This title appears in the Scientific Report :
2020
Please use the identifier:
http://dx.doi.org/10.1136/jnnp-2019-322614 in citations.
Please use the identifier: http://hdl.handle.net/2128/25316 in citations.
A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up
A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson’s disease (PD).Methods Here we report the 36-month follow-up of a prospective, observational, contro...
Saved in:
Personal Name(s): | Jost, Stefanie Theresa (Corresponding author) |
---|---|
Sauerbier, Anna / Visser-Vandewalle, Veerle / Ashkan, Keyoumars / Silverdale, Monty / Evans, Julian / Loehrer, Philipp A / Rizos, Alexandra / Petry-Schmelzer, Jan Niklas / Reker, Paul / Fink, Gereon Rudolf / Franklin, Jeremy / Samuel, Michael / Schnitzler, Alfons / Barbe, Michael Thomas / Antonini, Angelo / Martinez-Martin, Pablo / Timmermann, Lars / Ray-Chaudhuri, K. / Dafsari, Haidar S (Corresponding author) | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | Journal of neurology, neurosurgery, and psychiatry, 91 (2020) 7, S. 687-694 |
Imprint: |
London
BMJ Publishing Group
2020
|
DOI: |
10.1136/jnnp-2019-322614 |
PubMed ID: |
32371534 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity |
Link: |
Restricted OpenAccess Restricted OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/25316 in citations.
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson’s disease (PD).Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen’s effect size. In addition, bivariate correlations of change scores were explored.Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and -complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly.Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments. |